Group items tagged

Living with diabetes can be managed by proper medication. However, you may have questions regarding the medications available to you. Here, we will take a closer look at two medications, Ozempic and Saxenda, so that you can see how these medications can impact your health. A CLOSER LOOK AT DIABETES Diabetes can be divided into two categories, type 1 diabetes (T1D) and type 2 diabetes (T2D). Type 1 diabetes is an autoimmune disorder and is commonly diagnosed in children. Individuals with T1D require lifelong insulin treatment to manage their diabetes. Type 2 diabetes is diagnosed later in life due to genetics, lifestyle, and other risk factors. Unlike T1D, there are numerous treatment options other than insulin therapy to manage type 2 diabetes. GLP-1 RECEPTOR AGONISTS A common drug class used to treat type 2 diabetes is glucagon-like peptide 1 (GLP-1) receptor agonists. GLP-1 receptor agonists work by lowering blood glucose and slowing gastric emptying. Benefits of using a GLP-1 receptor agonist include: weight loss, atherosclerotic cardiovascular disease (ASCVD) benefits, lowering A1C values, and chronic kidney disease (CKD) benefits with little risk of hypoglycemia. Common GLP-1 receptor agonist side effects include nausea, vomiting, diarrhea, weight loss, and injection site reactions. GLP-1 receptor agonists should not be used in patients with a personal or a family history of medullary thyroid cancer.

A study conducted by Michigan Medicine revealed that individuals who experience type 2 diabetes over an extended period are increasingly prone to experiencing alterations in their brain structure. A group of scientists examined data from 51 middle-aged Pima American Indians who were diagnosed with type 2 diabetes. They employed a set of memory and language assessments known as the NIH Toolbox Cognitive Battery, developed by the National Institutes of Health, alongside MRI scans. These analyses aimed to establish the connection between diabetes, cognitive function, and the composition of the brain. Brain imaging suggested that study participants with longer durations of type 2 diabetes had decreased mean cortical thickness and gray matter volumes, and an increased volume of white matter hyperintensities. The MRI results, researchers say, indicate the negative effects longstanding diabetes may have on brain health outcomes and emphasise the importance of preventing early onset type 2 diabetes.

One type of bacteria found in the gut may contribute to the development of Type 2 diabetes, while another may protect from the disease, according to early results from an ongoing, prospective study led by investigators at Cedars-Sinai. The study, published in the peer-reviewed journal Diabetes, found people with higher levels of a bacterium called Coprococcus tended to have higher insulin sensitivity, while those whose microbiomes had higher levels of the bacterium Flavonifractor tended to have lower insulin sensitivity. Mark Goodarzi, the director of the Endocrine Genetics Laboratory at Cedars-Sinai in Los Angeles, California, is leading an ongoing study that is following and observing people at risk for diabetes to learn whether those with lower levels of these bacteria develop the disease. "The big question we're hoping to address is: Did the microbiome differences cause diabetes, or did diabetes cause the microbiome differences?" said Goodarzi, who is the senior author of the study and principal investigator of the multicenter study called Microbiome and Insulin Longitudinal Evaluation Study (MILES).

The NHS Diabetes Prevention Programme, which was introduced in England in 2016, is helping hundreds of thousands of people to lead healthier lives. People with pre-diabetes are being identified and offered a nine-month behaviour change programme that supports healthier diet and exercise choices to reduce their risk of developing diabetes. A study funded by the National Institute for Health and Care Research (NIHR) has found a significant reduction in diabetes risk among patients who had been referred to the NHS programme. Three years after their referral, the participants were 20 per cent less likely to have type 2 diabetes than a similar person who was not included in the programme, the evaluation revealed.

Living with diabetes can be difficult, but it is important to remember that you are not alone. Millions of people around the world are living with diabetes every day. This article will discuss some tips on how to better handle your diabetes. It will also provide information on the latest treatments and technologies available to help make managing your diabetes easier than ever before! 1) METHOD OF INSULIN DELIVERY There are a variety of methods for insulin delivery, each with its own benefits and drawbacks. One of the most common methods is injections. Insulin injections are quick and easy, and they allow you to have more control over your blood sugar levels. However, some people find them to be painful or inconvenient. As seen at DiaBettr, there are also insulin pens available that can make injections less painful and more convenient. Another method of insulin delivery is through an insulin pump. Insulin pumps are small, wearable devices that deliver insulin to your body constantly throughout the day. They are very effective at keeping your blood sugar levels in control, but they can be expensive and require a lot of maintenance.

How To Prevent Diabetes Type 2? You have just discovered that you are prediabetic. You can take meaningful steps to reduce your risk of diabetes. You can actually prevent diabetes simply by changing what you eat and how you invest in your physical health. The ball, my friend, is still in your court.

Around 8.3 percent population in the US has diabetes. Type II is the most prevalent form of diabetes. It is common among the young and the obese. Diabetes Mellitus or simply diabetes is a group of metabolic disorders characterized by an increase in your blood sugar. This results from an inadequate amount of insulin in the body or the cells' inability to respond to insulin.

Type 1 diabetes patients can monitor their glucose with the newly introduced flash glucose monitors by the NHS. The wearable gadgets with the size of a £2 coin, have a sensor that easily sits on the arm, allowing patients to check their glucose levels with a one-second scan. Eligible patients are currently able to access the monitors on prescription from their local GP or diabetes team, helping them to better manage their blood sugar levels. Everyone living with type 1 diabetes will be eligible for lifechanging flash glucose monitors on the NHS. The NHS Long Term Plan has already helped almost three in five people with Type 1 diabetes to access the monitors that allow people to check their glucose levels more easily and regularly. The change, confirmed today by the National Institute for Health and Care Excellence (NICE), means that everyone in England with the condition will be able to benefit from the convenient technology.

Diabetes is a major cause of blindness, kidney failure, heart attacks, stroke, and lower limb amputation. In 2019 diabetes was the ninth leading cause of death with an estimated 1.5 million deaths. but, you can manage your diabetes naturally. Visit link to know more about Effective Home Remedies for Diabetes Type-II

The National Health Services England (NHSE) is poised to revolutionise diabetes management with the introduction of the 'artificial pancreas', also known as the Hybrid Closed Loop system, to treat type 1 diabetes. This pioneering initiative, endorsed by the National Institute of Health Care and Excellence (NICE), represents a global first in healthcare innovation. With 269,095 individuals grappling with type 1 diabetes in England, the Hybrid Closed Loop system is set to cater to tens of thousands of children and adults across the nation. This cutting-edge device operates by seamlessly monitoring blood glucose levels and autonomously adjusting insulin dosage through a pump, by eliminating the need for regular insulin injections. Furthermore, it holds the promise of averting life-threatening hypoglycaemic and hyperglycaemia episodes, mitigating significant risks associated with the condition. To facilitate the identification of beneficiaries, NHSE has allocated a substantial sum of £2.5 million, ensuring that those who could benefit from this innovative solution receive the necessary support.

In partnership with the pharmaceutical company Boehringer Ingelheim, Leeds Teaching Hospitals Trust (LTHT) has recently established an innovative cardiometabolic clinic. The clinic focuses on reducing cardiovascular risk in people with diabetes who have recently been discharged from LTHT following a heart attack. It is delivered jointly by the cardiology department at Leeds General Infirmary and the diabetes services at the Trust. This is a patient-centred approach to reducing that risk, with pharmacist-delivered clinics scheduled for six to eight weeks after the heart attack. Stephen Wheatcroft, Professor of Cardiometabolic Medicine and Consultant Cardiologist at LTHT, said: "This is an exciting and innovative development, one of the first in the country. Previously, Type 2 diabetic patients presenting with heart issues would have been treated by two separate specialty teams. This is the first time there has been a specific clinic combining the cardiac and diabetes team working together. "We aim to reduce the risk for patients, with earlier multidisciplinary hospital care, to help discharged patients achieve better diabetes control, through improved medication support and optimisation, reducing the need for further treatment and future hospital stays. Overall, it will mean a better patient experience, with improved monitoring and information about treatment options, along with a reduction in waiting times for review in a specialist clinic."

In an announcement following Keir Starmer's and Wes Streeting's visit to a hospital in the East Midlands, Labour Party has unveiled a groundbreaking partnership with Virgin Media O2 aimed at ensuring every child with type 1 diabetes can access the latest medical technology to better manage diabetes. With the NHS providing patients with type 1 diabetes the option of an 'artificial pancreas' in the next five years to manage insulin levels and Continuous Glucose Monitors launched nearly 2 years ago to monitor children's glucose levels, the initiative aims to address the financial barrier hindering hundreds of families from benefiting from this breakthrough. Labour's plan to provide every child in need a smartphone, facilitating access to modern glucose monitors, aligns with the centre-leftist party's broader vision to harness technology for healthcare transformation. Announcing the partnership in an interview with ITV News, Keir Starmer, Labour Party Leader, highlighted the lack of equitable access to medical advancement amongst patients as "travesty" and "impact of fourteen years of Conservative chaos has had on the NHS", stating:

National Institute of Health and Care Excellence (NICE) has not recommended 'Tirzepatide', also known as Mounjaro, developed by Eli Lilly, in its draft guidance issued on Tuesday (27 June) for treating type 2 diabetes in adults alongside diet and exercise. The independent NICE committee recognised the importance of new treatment options given that fewer than two-thirds of the adults with type 2 diabetes have adequate glucose control when using current treatment options. Evidence submitted to the committee from clinical trials showed the use of tirzepatide at any dose resulted in better glucose control and lower weight compared with semaglutide or insulin therapy. The weight reduction was more pronounced with higher doses of tirzepatide, while the effect on glucose levels seemed less dose-dependent. Similar effects were observed against all GLP-1 receptor agonists in company's network meta-analysis, but this was uncertain. The committee have asked the company to provide more data to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for GLP-1 receptor agonists used in the management of type 2 diabetes on Tuesday (27 June). "There are very limited, intermittent supplies of all glucagon-like peptide-1 receptor agonists (GLP-1 RAs) licensed in the management of Type 2 Diabetes Mellitus (T2DM)," said DHSC. The supply issues have been caused by an increase in demand for these products for licensed and off-label indications and it is not expected to return to normal until at least mid-2024. Pharmacists are urged to refer to the SPS Tool for Medicines Shortages for an up-to-date supply stock situation and clinical guidance on alternative treatment options.

Burning the candle at both ends during the working week could raise a person's risk of developing type 2 diabetes, New York researchers say. People who slept fewer than six hours a night were more likely to develop a condition that precedes diabetes than those sleeping for longer, they found. They said the study supported mounting evidence that cutting back on sleep can have a profound impact on health.

Eli Lilly's weight-loss medicine Mounjaro, also known as tirzepatide, will be available in the UK within weeks as a four-dose pre-filled injection pen. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the drug to treat adults with type 2 diabetes and for weight management in obese patients. Branded as Mounjaro KwikPen, the injection is to be used together with a reduced-calorie diet and increased physical activity, the regulator said. "The public health importance of safe and effective treatments to help manage diabetes and obesity, which can have a significant impact on people's health, is clear. "This approval enables access to the approved Mounjaro pen in a more convenient presentation of a month's treatment, of one dose per week," said Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access.

Have you ever wondered about the health benefits of ginseng? It's been used for thousands of years by people in Asia and Eastern Europe, but did you know it's good for more than just boosting energy? The ginseng plant deals with 11 combinations of short, slowly growing plants with fleshy roots. It can revive and improve well-being. This article will explore how this herbal plant can benefit your body. 11 Health Benefits of the Ginseng Plant There are two types of ginseng plants mainly: Asian or Korean ginseng (Panax ginseng) American ginseng (Panax quinquefolius). Studies have discovered that the distinct types have various uses. American ginseng is believed to be less stimulating in traditional Chinese medicine than the Asian one. There are several other herbs known as ginseng, like eleuthero or Siberian ginseng, but they don't have the valuable content of ginsenosides. Ginseng has traditionally been used for several medical illnesses. However, its benefits for most of them have yet to be thoughtfully researched. These include: 1/11_It may help your lungs work better. ginseng plant lowers lungs infections.Ginseng may also help your lungs, according to a published study in the Journal of Ethnopharmacology. Researchers found that one of the active ingredients in ginseng, ginsenoside Rg1 has an anti-inflammatory effect on the lungs and can even protect against asthma and bronchitis. They found that rats with asthma had less inflammation after being given doses of ginseng for two weeks compared to rats not given any. They also observed that rats with pneumonia had fewer symptoms when they were treated with inhaled doses of ginsenoside Rg1 or orally administered doses of Korean red ginseng extract (KRGE). 2/11_It may lower blood sugar levels. ginseng plant lower blood sugar levels. It's not just your imagination-ginseng can help lower blood sugar levels in people with diabetes. It also has been proven to reduce the amount of cholesterol in your body. It

When you leave your doctor's office, do you ever wonder what he's not telling you? Every appointment, he tells you to eat less sugar and go on more walks, but aren't there other ways to get your diabetes under control? Ever wish you could REVERSE your Type 2 Diabetes? Discover 3 Proven Steps with this discovery from a recent Newcastle University medical study

Have you been medically proven to have type 2 diabetes, and it seems like your whole life is crashing right on you? Or, you are not sure what is happening but you are experiencing tingling, pain, or numbness in the hands and feet, blurry vision, extreme fatigue, excessive urination, and you often have cuts/bruises that are slow to heal? All you need right now is paying maximum attention to every detail about the Halki diabetes remedy...click link for more

A diabetes medicine, Mounjaro, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat overweight patients. The weight loss medication originally developed for Type 2 diabetes is now accessible to individuals aged 18 and over who are dealing with obesity and weight-related health issues. The active ingredient, tirzepatide, works by making the patient feel fuller and reducing food cravings. The injection helps individuals lose 20 per cent of their body weight, and are advised to follow a reduced-calorie diet and increase physical activity simultaneously. Although it is not authorised to use on the NHS as yet but future approvals can be predicted.

The Department of Health and Social Care (DHSC) has issued an alert to update healthcare professionals on the shortage of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are used to treat type 2 diabetes. It has informed that the supply of the drugs continues to be limited, and is not expected to return to normal until at least the end of 2024. An increase in demand for these products for licensed and off-label indications is cited as the cause of the supply issues. "Rybelsus® (semaglutide) tablets are now available in sufficient quantities to support initiation of GLP1 RA treatment in people with type 2 diabetes (T2DM) in whom new initiation of GLP-1 RA therapy would be clinically appropriate," the DHSC's National Patient Safety Alert reads.